Lepu Medical Tech Beijing - Asset Resilience Ratio
Lepu Medical Tech Beijing (300003) has an Asset Resilience Ratio of 1.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Lepu Medical Tech Beijing's Asset Resilience Ratio has changed over time. Check 300003 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Lepu Medical Tech Beijing's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lepu Medical Tech Beijing stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥350.77 Million | 1.37% |
| Total Liquid Assets | CN¥350.77 Million | 1.37% |
Asset Resilience Insights
- Limited Liquidity: Lepu Medical Tech Beijing maintains only 1.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lepu Medical Tech Beijing Industry Peers by Asset Resilience Ratio
Compare Lepu Medical Tech Beijing's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Lepu Medical Tech Beijing (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Lepu Medical Tech Beijing.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.78% | CN¥203.31 Million ≈ $29.75 Million |
CN¥26.14 Billion ≈ $3.82 Billion |
-0.34pp |
| 2024-12-31 | 1.12% | CN¥274.86 Million ≈ $40.22 Million |
CN¥24.57 Billion ≈ $3.60 Billion |
+0.02pp |
| 2023-12-31 | 1.10% | CN¥275.20 Million ≈ $40.27 Million |
CN¥25.02 Billion ≈ $3.66 Billion |
-0.03pp |
| 2022-12-31 | 1.13% | CN¥277.21 Million ≈ $40.57 Million |
CN¥24.48 Billion ≈ $3.58 Billion |
+0.85pp |
| 2021-12-31 | 0.29% | CN¥59.28 Million ≈ $8.67 Million |
CN¥20.70 Billion ≈ $3.03 Billion |
+0.17pp |
| 2020-12-31 | 0.11% | CN¥20.63 Million ≈ $3.02 Million |
CN¥18.26 Billion ≈ $2.67 Billion |
+0.05pp |
| 2019-12-31 | 0.06% | CN¥10.00 Million ≈ $1.46 Million |
CN¥15.93 Billion ≈ $2.33 Billion |
-1.07pp |
| 2018-12-31 | 1.14% | CN¥171.74 Million ≈ $25.13 Million |
CN¥15.10 Billion ≈ $2.21 Billion |
-0.28pp |
| 2017-12-31 | 1.42% | CN¥181.74 Million ≈ $26.59 Million |
CN¥12.79 Billion ≈ $1.87 Billion |
+1.21pp |
| 2016-12-31 | 0.21% | CN¥20.21 Million ≈ $2.96 Million |
CN¥9.50 Billion ≈ $1.39 Billion |
-0.10pp |
| 2015-12-31 | 0.31% | CN¥24.29 Million ≈ $3.55 Million |
CN¥7.73 Billion ≈ $1.13 Billion |
-58.94pp |
| 2009-12-31 | 59.25% | CN¥1.10 Billion ≈ $160.86 Million |
CN¥1.86 Billion ≈ $271.47 Million |
+59.25pp |
| 2008-12-31 | 0.01% | CN¥35.88K ≈ $5.25K |
CN¥609.24 Million ≈ $89.15 Million |
-- |
About Lepu Medical Tech Beijing
Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management. It offers medical devices, including cardiovascular devices, in vitro d… Read more